Sandhya Sapra, PhD

Senior Director
Value Evidence and Outcomes, GlaxoSmithKline

Poster(s):

• (332) Burden of Administration: Belantamab Mafodotin (Belamaf) Combinations vs Isatuximab (Isa) + Carfilzomib (K) + Dexamethasone (d), Daratumumab (D) + K + d, and K + d in Relapsed/Refractory Multiple Myeloma (RRMM)
  Wednesday, October 29, 2025